Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity
Seungjin Ryu, … , Yun-Hee Youm, Vishwa Deep Dixit
Seungjin Ryu, … , Yun-Hee Youm, Vishwa Deep Dixit
Published October 2, 2023
Citation Information: J Clin Invest. 2023;133(19):e169173. https://doi.org/10.1172/JCI169173.
View: Text | PDF
Research Article Inflammation Metabolism

Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity

  • Text
  • PDF
Abstract

The comprehensive assessment of long-term effects of reducing intake of energy (CALERIE-II; NCT00427193) clinical trial established that caloric restriction (CR) in humans lowers inflammation. The identity and mechanism of endogenous CR-mimetics that can be deployed to control obesity-associated inflammation and diseases are not well understood. Our studies have found that 2 years of 14% sustained CR in humans inhibits the expression of the matricellular protein, secreted protein acidic and rich in cysteine (SPARC), in adipose tissue. In mice, adipose tissue remodeling caused by weight loss through CR and low-protein diet feeding decreased, while high-fat diet–induced (HFD-induced) obesity increased SPARC expression in adipose tissue. Inducible SPARC downregulation in adult mice mimicked CR’s effects on lowering adiposity by regulating energy expenditure. Deletion of SPARC in adipocytes was sufficient to protect mice against HFD-induced adiposity, chronic inflammation, and metabolic dysfunction. Mechanistically, SPARC activates the NLRP3 inflammasome at the priming step and downregulation of SPARC lowers macrophage inflammation in adipose tissue, while excess SPARC activated macrophages via JNK signaling. Collectively, reduction of adipocyte-derived SPARC confers CR-like metabolic and antiinflammatory benefits in obesity by serving as an immunometabolic checkpoint of inflammation.

Authors

Seungjin Ryu, Olga Spadaro, Sviatoslav Sidorov, Aileen H. Lee, Sonia Caprio, Christopher Morrison, Steven R. Smith, Eric Ravussin, Irina Shchukina, Maxim N. Artyomov, Yun-Hee Youm, Vishwa Deep Dixit

×

Figure 1

Inhibition of SPARC by CR is associated with improved metabolic outcomes in humans.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of SPARC by CR is associated with improved metabolic outcomes...
(A) Study design and adipose tissue sample collection from human CALERIE-II study for the transcriptomic analyses. (B and C) Information of study participants that underwent 14% sustained CR and weight loss and provided adipose tissues for RNA-Seq. (D) Baseline RPKM of significantly downregulated genes (Padj < 0.05, FC < –1.5) in RNA-Seq with human adipose tissue after 1 and 2 years of CR. (E) Heatmap of gene expression changes ranked by RPKM for top 30 genes that are significantly downregulated (Padj < 0.05, FC < –1.5) from baseline to year 1 or year 2. The colored circles indicate genes that are significantly downregulated in 1 year only (green), 2 years (blue), or both (red). (F) Regression analyses between percentage changes of SPARC, normalized expression, and percent changes in BMI, body fat percentage (upper), CRP, and ICAM1 (lower) of participants with 2 years of CR (n = 8). (G) q-PCR analysis of SPARC in human adipocytes, T cells, and monocytes (n = 6). (H) q-PCR analysis of SPARC mRNA from primary adipocytes isolated from SAT of overweight children before and after 8 weeks of CR (n = 6). Error bars represent the mean ± SEM. 2-tailed unpaired and paired t tests (C and H), 1-way ANOVA with Dunnett’s multiple comparisons test for adjusted P values (G), and Pearson correlation analysis (F) were performed for statistical analysis. *P < 0.05; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts